André Ulmann, founder and chief executive of HRA Pharma, a French healthcare company, has been appointed to the supervisory Board of BioAlliance Pharma SA. Dr Ulmann is an expert in reproductive health, having identified the therapeutic need for emergency contraception more than a decade ago and subsequently establishing HRA Pharma as a pioneer in this field. He received his MD degree from the University of Paris VII and his PhD in science from the University of Paris VI.
BioAlliance Pharma has also appointed Denis Biju-Duval, head of private equity at the bank, ING Belgium, to the supervisory board.
Copyright 2009 Evernow Publishing Ltd